HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

HC Wainwright & Co. analyst Joseph Pantginis has maintained a 'Buy' rating on Iovance Biotherapeutics (NASDAQ: IOVA) and raised the price target from $9 to $20. This adjustment reflects a positive outlook on the company's performance.